SsrI endonuclease

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184

In the pooled SSRI arms (sertraline and fluoxetine combined, n=145), early improvement in the HAM-D-17 anxiety-psychic item from baseline to week 1 was significantly associated with remission at study

Effect: improvement; p<0.001, r2=0.184